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ABSTRACT 
Objective 
Nasal continuous positive airway pressure (NCPAP) is the most commonly used respiratory 
support for newborn infants. It is a technique for non-invasive respiratory support of both 
term and preterm infants with respiratory distress. NCPAP is preferred to mechanical 
ventilation in preterm infants after several clinical trials showed equal or improved outcome 
when it is used as primary support. Finding treatment strategies that reduce the need for 
intubation and mechanical ventilation to improve outcome and survival, have been a core 
theme in neonatal research. 
There is a wide range of NCPAP systems and little information to facilitate the choice. This 
leaves the clinician with multiple options and uncertainties. Research on performance as well 
as optimising and combining NCPAP with resuscitation systems, has the potential to further 
reduce the need for mechanical ventilation and improve outcome. The aim of this thesis is to 
describe the performance of continuous positive airway pressure (CPAP) systems (1), to 
evaluate techniques for measuring flows during CPAP treatment (2) and to develop a new 
system for neonatal resuscitation (3). 
Methods 
1) A mechanical lung model was used to measure pressure stability and the imposed work of 
breathing (WOB) during simulated breathing. The tests of CPAP systems included different 
levels of CPAP, breathing profiles and leakage.  
2) Flow meters were evaluated in the mechanical lung model using the in-line and the flow-
through placement technique. 
3) Infant resuscitation system prototypes were designed, manufactured in 3D printers and 
tested for pressure stability in the mechanical lung model. The final design was tested in a 
clinical feasibility trial. 
Results 
1) The tested CPAP systems showed large differences in pressure stability and imposed 
WOB.  
2) The flow meters intended for neonatal use had a higher resistance and lower dead space 
than the other tested flow meters. In-vitro tests in the flow-through position showed that 
resistance generated CPAP. Two flow meters with low resistance had acceptable flow 
recording quality in the flow-through position.  
3) In simulated spontaneous breathing, the new resuscitation system (prongs or facemask 
interface) had a marked reduction in imposed WOB compared to standard T-piece 
resuscitators. The clinical feasibility trial of 36 preterm infants did not reveal any problems 
with safety or usage of the new system. 
Conclusions 
1) The clinical importance of pressure stability for CPAP systems and imposed WOB is 
unclear but has been suggested as an important factor for some premature infants. This should 
be considered when choosing CPAP systems, designing trials and interpreting results.  
2) Measuring breathing during nasal CPAP seems possible with the flow-through technique. 
This should result in measurements with no added WOB or dead space. 
3) The new infant resuscitation system has low imposed WOB and will allow future 
investigations of the importance of imposed WOB, patient interfaces and CPAP levels.  
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BPD Bronchopulmonary dysplasia 
CI Confidence interval 
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CPAP Continuous positive airway pressure 
ET-tube Endotracheal tube 
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iWOB Imposed work of breathing 
NCPAP Nasal continuous positive airway pressure 
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NIPPV Non-invasive positive pressure ventilation 
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PPV Positive pressure ventilation 
RCT Randomised controlled trial 
RDS Respiratory distress syndrome 
RIP Respiratory inductive plethysmography 
SpO2 Peripheral capillary oxygen saturation 
TV Tidal volume 
VLBW Very low birth weight 
WOB Work of breathing 
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1 INTRODUCTION 
Preterm birth is a major cause of death and disability worldwide. Approximately ten percent 
of infants are born prematurely and the absolute number of preterm infants is increasing.1 
There has been a remarkable progress in respiratory support for the preterm neonate since 
nasal continuous positive airway pressure (NCPAP) was introduced by Gregory in 1971.2 
The decreased mortality and morbidity has been attributed to a number of factors including 
non-invasive respiratory support, improved antenatal care and intensive care in general.  
NCPAP is used in both term and preterm infants with respiratory distress. In preterm infants 
it is commonly used after birth and after extubation (following a period of mechanical 
ventilation).3,4 NCPAP was, on average, used for more than a month in extremely preterm 
infants born in Sweden in 2014 (Swedish Neonatal Quality Register annual report 2014).  
A core aim for neonatal research has been to find techniques or strategies to reduce the need 
for mechanical ventilation. The approaches include both pharmaceutical therapies and 
respiratory support techniques. Intubating and mechanically ventilating infants has been 
associated with worse outcome compared to using NCPAP.5 Optimising existing NCPAP 
treatment has the potential to further improve respiratory care of preterm infants. This may 
reduce the number of infants that fail on NCPAP and the need for mechanical ventilation. A 
high risk of failing on NCPAP is seen in infants born at lower gestational age, when receiving 
NCPAP directly after birth or when extubated from mechanical ventilation.6,7  
The development of new tools for respiratory support and optimisation of non-invasive 
management could allow more infants to breathe on their own and reduce the need for 
intubation and mechanical ventilation (invasive). The research presented in this thesis 
concerns basic questions on the performance of NCPAP systems, flow measuring techniques 
and resuscitation equipment. In order to be meaningful the preclinical investigations have to 
result in clinical research.  
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2 BACKGROUND 
2.1 EFFECTS OF NCPAP 
NCPAP applies a continuous distending pressure to the spontaneously breathing infant 
through a non-invasive interface. The positive effects of NCPAP have been explained using 
physiological reasoning in combination with studies in animals and humans.8,9 These include: 
• Splinting of upper airway leading to decreased resistance and avoidance of 
obstructive apnoea 
• Splinting of the thorax attenuates chest wall distorsion during inspiration 
• The distending pressure leads to increased functional residual capacity (FRC) with 
improved oxygenation and elimination of carbon dioxide 
• Decreased shunting and improved ventilation 
• Improved compliance and lower work of breathing 
• Conservation of surfactant 
• Reduced apnoea 
Negative effects of NCPAP are risks of pneumothorax, lung over-inflation (leading to 
decreased compliance, increased work of breathing (WOB), reduced ventilation and reduced 
venous return) and gas entering the gastrointestinal tract. The patient interface poses a risk of 
nasal damage.9 
2.2 HISTORY OF NCPAP 
The concept of CPAP to support infants is more than a hundred years old. In 1911, 
Engelmann provided a detailed description of an infant face mask resuscitation system with 
bubble CPAP developed from von Tiegel's apparatus (original illustration on the thesis 
cover).10 The manuscript focused on infant resuscitation with positive pressure ventilation 
(PPV) and positive end expiratory pressure (PEEP) but it also mentioned CPAP support 
during spontaneous breathing. The system was included in 'Die Krankheiten des 
Neugeborenen', a textbook by August Ritter von Reuss published in 1914, translated into 
English in 1921.11,12 
In 1971, Gregory described CPAP as a primary treatment for preterm infants with respiratory 
distress syndrome (RDS).2 After initial success the use and popularity declined. Mechanical 
ventilation was generally seen as a better alternative in North America and the UK but 
NCPAP remained popular in Denmark, Sweden and some centres in North America. The 
controversy between these two competing treatment traditions has been described by 
Lagercrantz.13  
The first observational study that reported differences in outcome related to the use of 
NCPAP was Avery in 1987.14 They described a lower incidence of bronchopulmonary 
dysplasia (BPD) and a less frequent use of mechanical ventilation in Columbia University, 
New York compared to seven other leading centres in North America. A subsequent 
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observational study by Horbar investigated the variability of BPD and mortality in 11 centres. 
Columbia reported good results and was the only centre practicing early CPAP instead of 
mechanical ventilation. The authors could not find a clear association between ventilation 
strategy (as reported by questionnaire) and outcome.15  
In a subsequent case-control study, Marter investigated predictors of chronic lung disease 
(CLD) comparing Boston and Columbia in infants born with a birth weight between 500 and 
1500 g.16 NCPAP was used as primary treatment in 11% in Boston vs 63% in Columbia. The 
CLD incidence (supplemental oxygen at 36 weeks postmenstrual age) was 22% in Boston vs 
4% in Columbia. They concluded that "CLD was predominantly associated with the decision 
to use mechanical ventilation".  
In Scandinavia, Kamper reported a comparably low incidence of BPD in a cohort of Danish 
infants 24 to 34 weeks of gestation treated with NCPAP.17 Jonsson reported outcome and 
treatment for 687 very low birth weight (VLBW) infants born in Stockholm 1988-93.18 The 
majority of patients could be managed without mechanical ventilation (59%) compared to 20-
30% in North American network reports. The CLD incidence in Stockholm was low 
compared to centres using more mechanical ventilation. The use of antenatal steroids in the 
cohort was low (20%) and during the study period routine surfactant became available (after 
1990). 
In a comparison between infants treated in Boston and Stockholm 2001-2003, the more 
invasive management in Boston was not associated with better outcome.19  
2.3 MECHANICAL VENTILATION, NCPAP AND SURFACTANT 
In the early 90's, the use of NCPAP increased but there were still no randomised controlled 
trials (RCT) comparing the effectiveness and safety of non-invasive ventilation to mechanical 
ventilation. At the same time the first trial of the delivery of surfactant in combination with 
NCPAP were published by Verder.20 In the following years, trials investigating invasive and 
non-invasive management of respiratory distress of premature infants had to address both 
respiratory support mode and surfactant treatment. 
2.3.1 Clinical trials comparing mechanical ventilation and NCPAP 
Initial respiratory support management of preterm infants include mechanical ventilation or 
non-invasive NCPAP support. The International Liaison Committee on Resuscitation 
(ILCOR) 2015 consensus document suggests the initial use of CPAP rather than intubation 
and mechanical ventilation (weak recommendation, moderate-quality evidence) referring to 
the COIN, SUPPORT and VON trials.21 The European RDS guidelines have the same 
recommendations referring to the COIN and SUPPORT trials.22 
Morley (COIN, 2008) randomised 610 infants (25-28 weeks of gestation) to either intubation 
or NCPAP.23 The intubation rate in the NCPAP group was 46% and surfactant could only be 
given after intubation. There was no difference between the groups in primary outcome in 
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terms of BPD or death (odds ratio (OR) in favour of CPAP 0,8 (0,58-1,12 95% confidence 
interval (CI))). There were differences in secondary outcome variables in favour of NCPAP 
(time on mechanical ventilation, death or oxygen therapy at 28 days of age). A safety concern 
was the higher incidence of pneumothorax in the NCPAP group.  
Finer (SUPPORT, 2010) randomised 1316 infants before delivery (24-27 weeks of gestation) 
to early CPAP or early intubation with surfactant.24 The intubation rate in the CPAP group 
was 32,6% in the delivery room and in total 83%. There was no difference between the 
groups in primary outcome in terms of BPD (OR in favour of CPAP 0,95 (0,85-1,05 95% 
CI)). There were differences in secondary variables in favour of CPAP (alive and free from 
the need for mechanical ventilation day 7, fewer days of ventilation). There were no safety 
concerns and no higher incidence of pneumothorax in the CPAP group. A post-hoc analysis 
of infants 24-26 weeks of gestation showed a lower rate of death in the CPAP group.  
Dunn (VON or sometimes DRM, 2011) randomised 648 infants (mean gestational age (GA) 
of 28 weeks) before delivery to 1) intubation, surfactant and minimum 6 h of mechanical 
ventilation 2) intubation-surfactant-extubation (referred to as ISX by the authors) or 3) 
NCPAP without surfactant.25 In the first hour after birth, 83,3% in the ISX group could be 
extubated and 82,1% in the NCPAP managed without intubation. The overall intubation rate 
was 59% in the ISX group and 52% in the NCPAP group. There were no differences between 
the groups in primary outcome of BPD or death. There were no safety concerns or higher 
incidence of pneumothorax in the NCPAP or ISX group. In other trials, intubation-surfactant-
extubation (ISX) is usually referred to as INSURE. 
The primary research question of these trials concerned mechanical ventilation and NCPAP. 
In summary these trials individually showed no negative effects of less invasive management 
on primary outcomes and some potential advantages on secondary outcomes. In meta-
analyses the trials showed a reduction in mortality and BPD (section 2.3.3). 
2.3.2 Clinical trials on NCPAP and Surfactant  
In 1994, Verder attempted to further reduce the need for mechanical ventilation in infants 
with RDS treated with NCPAP.20 They randomised 68 infants (25-35 weeks GA) to receive 
INSURE (intubation-surfactant treatment-extubation) or to continue NCPAP treatment. 
Infants that received INSURE were treated with NCPAP after extubation. The trial was 
stopped early because of the less frequent need for mechanical ventilation in the infants who 
received INSURE.  
The INSURE concept of rescuing patients on NCPAP that develop RDS has been 
investigated in several trials. The questions of delivering surfactant during NCPAP are 
complex and the effects of treatment depend on several factors including 1) use of antenatal 
steroids and the gestational age 2) timing of delivery (level of respiratory distress) 3) 
technique of delivery.  
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2.3.2.1 Prophylactic or selective treatment 
The early success of surfactant was investigated at a time when antenatal steroid use was low 
and many infants were intubated. Surfactant treatment can be given prophylactically to all 
patients and this has been compared to rescue (or selective) treatment to patients who 
developed respiratory distress. Rojas-Reyes highlighted the change in practice in a Cochrane 
review on prophylactic versus selective surfactant treatment; "In recent years, the increased 
utilisation of antenatal steroids, more gentle resuscitation in the delivery room and the routine 
use of early delivery room CPAP may have changed the risk/benefit analysis".26 The review 
had to include several subgroup analyses based on routine CPAP application, use of antenatal 
steroids and infants less than 30 weeks gestation. In summary, the benefits of prophylactic 
surfactant treatment are diminished in trials with routine application of CPAP and high use of 
antenatal steroids. Based on data from VON and the SUPPORT trial they conclude "in fact, 
the risk of CLD or death is lower in the arm that allowed stabilisation on CPAP and selective 
treatment with surfactant compared with the prophylactic arm". 
2.3.2.2 Timing of selective treatment 
One factor that has influenced the outcome in trials of surfactant rescue during NCPAP is the 
timing.27,28 The threshold for giving surfactant has been lowered and early rescue has been 
favoured over late rescue.27 
In a trial by Verder (1999) they randomised 60 infants (trial stopped early) with RDS on 
NCPAP to either early surfactant treatment or waiting until they were more affected (late 
treatment).29 The early treated infants had better outcomes.  
The Cochrane review of surfactant prophylaxis versus rescue excluded two trials due to an 
'early strategy'.26 The CNRN trial was excluded because the prophylaxis arm had signs of 
RDS at randomisation and was considered to be early strategy rather than prophylaxis.30 The 
CURPAP trial was excluded because the rescue arm was given surfactant as an early 
selective strategy rather than at established RDS.31 
Rojas (CNRN, 2009) randomised 279 infants with signs of respiratory distress (27-31 weeks 
of gestation) to NCPAP or NCPAP with prophylactic surfactant (INSURE) at 15-60 minutes 
of age.30 There was a difference in the primary outcome of mechanical ventilation in favour 
of prophylactic surfactant (OR 0,69 (0,49-0,97 95% CI)) and fewer pneumothoraces (OR 
0,25 (0,07-0,85 95% CI)). The NCPAP group received very late surfactant rescue at Fraction 
of inspired oxygen (FiO2) of >0,75 and this may have affected the outcome in the NCPAP 
control group. The difference could not be seen in the CURPAP trial or in the VON trial. 
Sandri (CURPAP, 2010) randomised 208 infants (25-28 weeks of gestation) at an age less 
than 30 minutes to NCPAP or NCPAP with prophylactic surfactant (INSURE).31 There was 
no difference in the primary outcome of mechanical ventilation within five days (33,0% 
NCPAP and 31,4% prophylactic surfactant) or any safety outcomes. 50 out of 103 (48,5%) of 
the patients in the NCPAP group needed surfactant (median age 240 minutes) and 16 of these 
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could be extubated (INSURE). In summary, they showed that the infants (spontaneously 
breathing, high use of antenatal steroids (78% complete and 19% incomplete course) and 25-
28 weeks of gestation) could be managed with NCPAP and selective surfactant administered 
to infants with respiratory distress.  
These two trials (CNRN and CURPAP) used early strategy or early selective strategy. This is 
presented in reviews as a promising way to further improve non-invasive management.26,27 
The review by Rojas highlights the reduced incidence of pneumothorax in early surfactant 
rescue (vs later).27  
An alternative to INSURE is to maintain spontaneous breathing and deliver surfactant 
without intubation and positive pressure ventilation. These techniques include intra-tracheal 
catheters, nebulisation and laryngeal devices.32 Delivery of surfactant by an intra-tracheal 
catheter placed by laryngoscopy (without mechanical ventilation) has received most attention. 
This has been investigated in several trials eg Göpel (AMV, 2011) and Kanmaz (Take Care, 
2013).33,34 Even though some trials have shown promising results, a concern has been raised 
regarding laryngoscopy (without or with minimal sedation) of infants with respiratory 
distress. 
Nebulisation of surfactant to a spontaneously breathing infant has advantages in theory but 
has been difficult to achieve.35,36 
2.3.3 Meta-analysis of less invasive NCPAP approach 
Schmölzer performed a meta-analysis and included 4 trials (COIN, SUPPORT, CURPAP and 
VON) with a total of 2780 preterm infants (<32 weeks GA).37 The pooled results for the 
combined outcome death or BPD showed a reduction in favour of delivery room NCPAP 
compared to intubation with a relative risk 0.90 (0.83-0.98 95% CI) and numbers needed to 
treat (NNT) of 25. 
Fischer and Bürer performed a review of strategies for avoiding intubation and BPD.5 This 
meta-analysis included three additional trials (in total 3289 patients) and showed a relative 
risk of 0,83 (0,71-0,96 95% CI) in favour of the NCPAP group. The authors concluded that 
"Regardless of the population studied and the strategy used, avoiding endotracheal 
mechanical ventilation consistently led to a reduction in the incidence of death or BPD in all 
trials, with odds ratios ranging from 0.63 to 0.97". The authors also reviewed evidence from 
observational studies and animal models and found further support for avoiding mechanical 
ventilation. 
There are still some controversy regarding the efficacy of NCPAP to reduce BPD. Jain and 
Bancalari refer to evidence as equivocal for NCPAP as preventing BPD (not considering the 
combined outcome of BPD or death) even when citing the meta-analysis by Fischer and 
Bürer.5,38  
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2.4 NCPAP SYSTEMS 
Since the introduction of CPAP by Gregory, many systems and interfaces for CPAP support 
have been developed.2 Early systems used expiratory resistors on the expiratory limb and a 
constant fresh gas flow (bias flow). The resistor was later replaced by submerging the 
expiratory limb into water to create a bubble CPAP. The next development was variable-flow 
CPAP systems. In these systems, CPAP is generated in the patient device, close to the 
interface, and adjusted with the fresh gas flow. In addition to these systems modern ICU 
ventilators are also capable of delivering CPAP by a Y-piece and a patient interface. All these 
techniques for CPAP generation are still in use. 
The wide range of systems and traditions leaves the clinician with multiple options and 
uncertainties. Even though the non-invasive NCPAP approach has proven superior to 
intubation and mechanical ventilation, there is little information to facilitate the choice of 
NCPAP system, prongs and the consequences of leakage or adjustment of CPAP level. 
Two other options of non-invasive treatment have also evolved. These are high-flow nasal 
cannulae and non-invasive positive pressure ventilation (NIPPV). Their clinical uses overlap 
with NCPAP treatment. The development of high-flow cannulae has been driven by creating 
more lightweight systems that are easier to apply and have less risk of nasal trauma without 
losing the benefits of NCPAP treatment. The aim of NIPPV development has been to avoid 
failure on NCPAP and further decrease the number of infants who need mechanical 
ventilation. Finding the boundaries and benefits of these alternatives to NCPAP is a major 
research challenge. These alternative treatment options will not be discussed in this thesis. 
2.4.1 Parts of NCPAP systems 
NCPAP systems can be constructed in several ways but generally consist of a fresh gas flow 
source, an interface and a CPAP generator.9 The CPAP generator can be positioned far away 
from the patient by using a Y-piece. This connects the expiratory and inspiratory tubing to the 
interface. Examples of the use of Y-piece connectors are the bubble NCPAP systems or 
NCPAP generated by ventilators. The variable-flow NCPAP systems use generators 
integrated with the patient interface. These were developed to increase pressure stability and 
the CPAP level is adjusted with the fresh gas flow.  
2.4.1.1 Fresh-gas flow source 
The fresh-gas flow allows adjustment of inspired oxygen concentration and usually provides 
an option for gas conditioning (heat and humidification). In ventilators and dedicated NCPAP 
drivers, recording of the delivered airway pressure allows features such as automatic 
adjustment of CPAP in response to leakage or high pressure alarms. 
2.4.1.2 Patient interface 
The original CPAP described by Gregory used endotracheal tubes for 18 patients and head 
chambers for two patients.2 In the following years, several non-invasive alternatives evolved.  
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A tight fitting face mask was reported in an abstract by Harris in 1972, Shannon in 1972 and 
Rhodes in 1973.39-41 Nasal masks were used by Chernick in 1973 and Cox in 1974.42,43 There 
were earlier reports of nasal interfaces, but they were used for pulmonary function tests and 
not for NCPAP.44-47 
Bilateral tubes in the posterior pharynx was used by Novogroder in 1973 and shorter binasal 
prongs by Kattwinkel in 1973, Agostino in 1973, Caliumi-Pellegrini in 1974 and Wung in 
1975.48-52 
Single nasal (cut endotracheal tubes (ET-tubes)) have also been used to provide CPAP. In a 
study by Field in 1985 it was said to have been used in "more recent years".53  
2.4.1.3 Techniques for CPAP generation 
NCPAP systems have been classified according to if the fresh-gas flow is constant or 
variable.9,54,55 This classification is difficult to apply to modern ventilators where adjustments 
of the inspiratory valve and fresh-gas flow are hidden from the user. Below is a classification 
of the principle mechanism for NCPAP generation.3 
Resistors placed on the expiratory limb will generate a CPAP when obstructing the bias 
flow. This resistor type of system was used by Gregory and referred to as a "modified Ayres 
T-piece" anaesthetic circuit.2,56 Gregory added a pressure meter and safety "underwater pop-
off ". It may be because of this safety feature that Gregory’s system sometimes has been 
incorrectly referred to as a bubble CPAP system.3,54,55,57-60.  
NCPAP resistor systems have been replaced by other techniques that are more pressure stable 
but are still being used in T-piece resuscitation systems. In the T-piece system the CPAP is 
generated by a valve situated on the patient end of the system. The resistance of this valve is 
adjustable but does not change during the breathing cycle (ie fixed but adjustable. 
The fixed area valves (such as the expiratory limb screw clamp used by Gregory) have 
sometimes been replaced by spring-loaded valves. This development was used by Wung in 
1975 and allows the valve area to increase and accept higher flows.52 From a pressure-
stability point-of-view the use of spring-loaded valves (or moving mechanical parts) for 
CPAP in neonates are problematic because of the small tidal volumes (TV) and rapid 
breathing. The spring-loaded valves are still in use when providing PPV with T-piece 
resuscitation systems or in anaesthetic circuits but generally not for NCPAP in infants. 
CPAP generated by ventilators are presented under a separate heading even if they use an 
expiratory valve (resistor) to generate CPAP. 
Bubble NCPAP uses a submerged tube as an expiratory limb resistor. The patient is 
connected to a Y-piece and the inspiratory limb connected to a bias flow. This modification 
of Gregory's circuit was mentioned by Novogroder and Caliumi-Pellegrini.48,51 Shannon used 
bubble CPAP in combination with a face mask a few years earlier and in their manuscript 
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they mention its use without referring to it as an invention.40 The first description of bubble 
CPAP for newborn infants was by Engelmann in 1911.10 
The fresh-gas flow (bias flow) is adjusted to a level at least high enough to compensate for 
maximal inspiratory flows. The tube submerged in water works as a pop-off valve. This gives 
a more pressure-stable NCPAP since the submerged tube has a large maximal area and no 
mechanical parts. The bubbles generate pressure oscillations in the respiratory circuit and 
possible benefits of this phenomenon have been discussed.61 
Variable-flow CPAP devices generate CPAP close to the patient interface. Most variable-
flow CPAP systems use turbulence to oppose expiration and aid inspiration. The first 
technique for this type of CPAP generation was developed in Denmark by Benveniste and 
Pedersen.62 The Benveniste valve uses a fresh-gas flow that is directed towards an orifice that 
is attached to the endotracheal tube. It was originally designed to work as a valve protecting 
intubated infants from ventilators and allowing spontaneous breathing with CPAP and low 
dead space. The Benveniste valve is a typical variable-flow CPAP device where CPAP can 
be increased or decreased by adjusting the fresh-gas flow. Even if it was originally described 
(1968) for invasive ventilation it was also used for non-invasive support (1976).63 There were 
other research groups working on similar concepts and in 1974 a light-weight low-resistance 
Venturi system was presented by Carden.56 This could "of course, easily be connected to 
nasal prongs or nasal mask, etc., if this less invasive method of delivering CPPB [continuous 
positive pressure breathing] is preferred".  
In the late 1980´s, a variable-flow generator was developed in Östersund, Sweden. This 
design used two short bi-nasal prongs connected to small "engines" that use turbulent flow to 
generate CPAP (Fig. 1).64 Pressure stability was achieved by the Venturi effect in 
combination with a "fluidic flip". This gave a light-weight system with increased pressure 
stability and low imposed work of breathing (iWOB). The system was later marketed as 
Infant Flow and the design has inspired other variable flow systems. 
The variable flow devices can be driven by any source capable of generating a fresh-gas flow. 
This can be a rotameter, an NCPAP driver or a ventilator. Electronically controlled drivers 
can be used to adjust the fresh-gas flow to compensate for leakage or to provide NIPPV by 
increased fresh-gas flow during inspiration. 
There is an overlap between variable-flow CPAP devices and resistor systems. This is a 
potential source of confusion for two reasons: 1) Any resistance on the expiratory side of a 
variable flow device will produce a system that is more similar to a resistor system 2) 
Increasing the fresh-gas flow to a resistor system will increase the delivered CPAP. An 
example of this is the Medin generator. It is based on resistance but referred to as a variable-
flow NCPAP (manuscript in preparation). 
Ventilators generate CPAP by balancing fresh-gas flow in the inspiratory limb with an 
expiratory valve on the expiratory limb. The patient is connected using a Y-piece. The 
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balance (inspiratory flow and expiratory resistance) is usually hidden from the user. If 
pressures are increased during inspiration NIPPV can be provided. Some ventilators provide 
NIPPV in CPAP mode.65  
The technical challenge of generating pressure stable NCPAP using a Y-piece is great 
because of tube compliance and system resistance in combination with rapid neonatal 
breathing and potential leakage at the interface. This is probably the reason why some 
ventilator manufacturers, instead of using a Y-piece, use the ventilator as a variable-flow 
NCPAP driver. The Y-piece and patient interface may look similar to variable-flow NCPAP 
devices which may be confusing.  
 
											 	
Figure 1: The original design of the variable flow NCPAP system developed by Gunnar Moa 
and Kjell Nilsson in Östersund. The device was later marketed as Infant Flow. A) Fresh gas 
flow inlet B) Connection to prongs C) Outlet. Left illustration from Moa with permission 
from Wolters Kluwer Health.64 Right photograph from Moa and Nilsson with permission 
from John Wiley and Sons.66 
2.4.2 Measuring pressure stability in-vitro 
When an infant is breathing through a CPAP device, the pressure in the patient's airway will 
fluctuate. During inspiration the airway pressure will decrease, whereas it will increase during 
expiration. These pressure changes are generated by the infant and represent the added work 
needed when breathing through a device, the so called imposed WOB. For pressure-unstable 
systems the fluctuations are larger and the additional work needed higher. This is not only 
applicable to NCPAP systems. The same principles apply in patients with endotracheal tubes, 
tracheostomies and airway obstruction. A typical example is the clinical concern when 
adding workload to the patient by the use of a narrow bore endotracheal tube. 
There are several ways to investigate pressure stability but they all reflect the relation 
between flow and pressure for a system or interface.  
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2.4.2.1 Static tests 
Pressure changes at a given flow is a simple way to describe resistance. Resistance was often 
described at one flow level for the first CPAP systems. For instance, Carden reports 3 mm 
H2O at 10 L/min (presumably expiratory flow) for their Venturi system and Kattwinkel 
reports less than 1 cm H2O at 3 L/min (direction of flow not stated) for their nasal unit.49,56 
Testing at multiple flow levels gives a more complete description. Goldman used a graphical 
display of prong resistance at flows 0-120 mL/s.67 De Paoli investigated prong resistances at 
4-8 L/min inspiratory flow with no CPAP applied.68 They showed that prongs with narrow 
internal diameter and greater length had higher resistance.  
An example of static tests is presented in figure 2. Neopuff and Infant Flow systems were 
tested at 5 cm CPAP with flow ranging from -10 to 10 L/min. The tilt and shape of the graph 
represents the resistance. The relation between pressure and flow is not linear or symmetrical. 
The advantage of static compared to dynamic testing is that the experiments are 
uncomplicated and do not require accurate reproduction of flow profiles or volumes.  
 
 
Figure 2: Example of static tests of two CPAP systems at 5 cm CPAP. Neopuff was tested at 
three levels of fresh-gas flows. Negative flows (ie inspiration) gives a reduction in delivered 
pressure. The slope represents pressure stability. Neopuff is less pressure stable than Infant 
Flow and the pressure stability is depending on fresh-gas flow. Lines represent means with 
error bars (95% CI). Data from manuscript in preparation. 
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2.4.2.2 Dynamic tests 
Dynamic tests use mechanical lung models. These can reproduce breathing and allow 
comparison of pressure stability during simulated breathing. Simulations can be either non-
compliant (volume or flow pump) or complex (including compliance and resistance).  
• Non-compliant models reproduce a flow or volume pattern. Variations in delivered 
volume or flow are only related to gas compression and compliance or resistance of 
tubing (if used). The use of these models aims at minimising the flow and volume 
variations during testing. 
• Models with compliance and resistance. Compliance and resistance can be achieved 
mathematically (programming of lung model) or physically (by deliberately adding 
resistors and compressible volumes). The delivered flow and volume will depend on 
changes in pressure and flow. This means that NCPAP systems that are not identical 
will not be tested at identical flows or volumes. The use of these models aims at 
mimicking in-vivo conditions. 
Models with compliance and resistance are difficult to work with since the standard variables 
for reporting pressure stability are dependent on reproducible flows and volumes. This 
problem has been highlighted by Natalini.69 They showed that attempts at compensating for 
variations in volume by using a volume adjusted work of breathing (WOB/L) were 
inappropriate. They also suggested a way to "eliminate the influence of the variable TV from 
the measure of WoB [Work of Breathing]" but the suggested correction has other 
disadvantages. Less complex variables such as the pressure difference during one breath 
(pressure swings) or pressure time product (PTP) also rely on reproducible volumes and do 
not solve the problem. 
Complex models have been used in studies that aim to simulate physiological work of 
breathing rather than just imposed work of breathing. For example in-vitro generation of 
Campbell diagrams.70 
 
There are few publications using compliant models. Cook used this method to investigat four 
CPAP systems.65 Their main outcome was TV delivered at the end of expiration and pressure 
drop during inspiration. One of the tested systems was a ventilator that provided not only 
CPAP but also low-level pressure support. Since they used a compliant model, the end 
expiratory TV (main outcome) will directly relate to end expiratory pressure. This 
methodological weakness will favour systems with pressure support (rather than CPAP). The 
other outcome variable, pressure drop during inspiration, will not be measured at identical 
flows. These problems were not discussed as limitations and not mentioned in the related 
editorial.54 
2.4.2.3 Measuring pressure stability in non-compliant dynamic models 
Models that aim to reproduce flow (or volume) allow direct comparison of variables that 
represent pressure stability.  
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Pressure: The pressures at a given time, flow or volume. For example, the lowest pressure 
(pressure decrease) or highest pressure (pressure increase) during one breath. 
Pressure time product: Integrating pressure change over a given time. This is rarely used and 
will not be discussed any further. 
Imposed work of breathing: Integration of pressure over volume for one breath.71 Total 
imposed WOB can be divided into an expiratory and inspiratory component. The work of 
breathing for any breath corresponds to the area within that single breath’s pressure-volume 
loop. Imposed work of breathing can also be averaged over time or per volume. 
 
2.4.3 In-vitro performance of NCPAP systems 
 
Moa (1988) compared a new device with a resistor system at three levels of CPAP and TV of 
30 mL.64 Pressure stability was measured as pressure changes and imposed WOB. The new 
device were more pressure stable than the resistor system and had a higher tolerance for 
leakage.  
Banner (1990) presented mechanical comparisons of CPAP delivered by ventilators and 
resistors in two abstracts.72 They showed highest imposed WOB with the Babybird and 
lowest with the Seachrist ventilator. In the resistor experiments they tested different valves in 
combination with the Seachrist or Babybird ventilator.72,73 The abstracts were never 
published as manuscripts. 
Klausner (1996) used a mechanical lung model to compare Arabella (Hamilton Medical) and 
a conventional resistor system with Hudson prongs.74 They used lower TV (12,1 mL) than 
Moa. The authors incorrectly refer to Arabella as the same system tested by Moa. Pressure 
stability is only reported as inspiratory imposed WOB (expiratory imposed WOB not 
reported) and pressure fluctuations (no detailed report). The results show a reduction in 
inspiratory imposed WOB for the Arabella device compared to the conventional resistor 
system.  
Nikischin (2011) reduced TV further (1-9 mL breaths) and investigated three systems at 5 cm 
CPAP in a custom built mechanical lung model (Dräger).75 A mono-nasal pharyngeal tube 
(3,0 mm internal diameter), Baby Flow nCPAP (Y-piece from Dräger) connected to a 
conventional ventilator (type and model not reported) and the Infant Flow system. Measured 
variables were pressure increase and decrease (from CPAP) and imposed WOB. They 
showed that mono-nasal pharyngeal tube had the highest imposed WOB followed by Baby 
Flow with a 20% reduction and Infant Flow (TV 4 mL) with 45%. They also performed 
simulations with leakage. The method of generating leakage exposed the systems to uneven 
test conditions with higher leakage for the more pressure stable Infant Flow system (not 
recognised nor discussed by the authors). A limitation to their description is that the Baby 
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Flow interface can be used with most ventilators and that the choice of ventilator will affect 
imposed WOB.  
Wald (2011) investigated expiratory resistance for seven NCPAP systems (TV 6 mL, peak 
flow 0,46 L/min) at a PEEP of 6 mbar (6,1 cm H2O).76 Resistance was measured by pressure 
change during expiration. They showed that the resistance was lowest with the Infant Flow 
device and highest with Neopuff (low fresh gas flow). The reduced expiratory resistance at 
higher flows with Neopuff is discussed in great detail. The fundamental problem with 
focusing on expiratory resistance is that the relation between resistance and total imposed 
WOB (expiratory and inspiratory) is lost. In the discussion the authors state that "The 
increase in PEEP during the expiration period demonstrated in our study causes a further 
increase in the RE [expiratory resistance] and should thus be considered an advantage for the 
patient". This controversial statement was left without further comments.  
Summary 
Tests of performance of NCPAP systems show that some systems consistently are more 
pressure stable than others despite large variations in methods and quality. The Infant Flow 
system has been reported as a pressure stable system with low imposed WOB in all 
publications. 
A problem in these in-vitro studies is that several authors generalise the performance of one 
system to a group of systems. For example, Cook drew conclusions on ventilator generated 
CPAP in general when they only tested one ventilator and Wald discuss the performance of 
jet systems in general when the two tested systems showed very different performance 
(Medijet and Infant Flow). 
2.4.4 Clinical importance of pressure stability and imposed WOB 
The differences in performance of NCPAP systems found in mechanical lung models could 
have clinical implications. Imposed WOB has been described as a factor that could affect 
outcomes such as failure on NCPAP and the subsequent need for mechanical ventilation.9,67 
The clinical effects of using different CPAP systems have been investigated with 1) cross-
over designs and short term physiological outcomes and 2) randomised controlled trials with 
clinical outcomes. 
Different hypotheses have driven this research. The compared systems have rarely been 
selected for their pressure stability but more often based on the type of CPAP generator, type 
of interface or local traditions.  
Pressure stability is only one of several factors that could affect outcome when comparing 
devices. The quality of the NCPAP delivered and the clinical effect will be a result of an 
interaction between the patient, interface and CPAP generator system. Trials of longer 
duration are also highly dependent on nursing care, training and the population studied.  
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2.4.4.1 Cross-over trials with physiological outcomes 
The effects of CPAP systems on physiological variables have been investigated in several 
cross-over trials (Table 1).60,77-85 The trials vary in the selected patients, outcomes, CPAP 
systems, patient interfaces, duration of treatment and CPAP levels.  
Five manuscripts were published between 2001-2011 by a group with Courtney and Habib as 
co-authors in all manuscripts (Courtney, Pandit and Liptsen in Table 1).60,78-81 They have 
investigated different CPAP systems using RIP standardised by pneumotachograph and 
oesophageal balloon catheter. In all studies, the systems were investigated at different CPAP 
levels. The duration at each level was approximately 5 minutes.  
A group in Lille, France, investigated the effects of CPAP levels on lung volumes and 
breathing patterns in two studies using RIP (without oesophageal balloon) and Infant 
Flow.86,87 They showed increased FRC (end-expiratory lung volume by RIP) and changes in 
breathing pattern (lower respiratory rate, loss of expiratory braking) with increased CPAP 
level. These effects are largely consistent with other reports.60,78-81 The same group published 
a randomised cross-over comparison of Infant Flow, the Dräger Babylog 8000 ventilator and 
no NCPAP in 13 infants weaned from mechanical ventilation (Boumecid in Table 1).84 Their 
main findings were higher TV, less expiratory braking and less thoraco-abdominal 
asynchronies with Infant Flow.  
One trial used direct measurement of breathing (Huckstadt in Table 1).83 They compared 
Infant Flow (short binasal prongs) and Babylog 8000 (single cut ET-tube, other nostril 
occluded) in newly extubated infants who needed NCPAP. Tidal breathing parameters were 
obtained from the airway flow using flow-through technique after a minimum of five minutes 
of accommodation. 20 infants were included after excluding 49 patients (leakage in 46 
patients, irregular breathing in two patients and apnoea in one patient). Infant Flow showed 
less pressure swings, increased peak flows and increased TV. They concluded that Infant 
Flow improved ventilation.  
Pickerd performed a trial on infants during weaning from CPAP (Pickerd in Table 1).85 They 
used a novel electromagnetic inductance plethysmography (EIP) (FloRight, Volusense AS, 
Oslo, Norway) and not the traditional RIP used by other groups. This included serial 
measurements of tidal breathing but they also performed a 15 min cross-over comparison of 
1) bubble CPAP 2) Infant Flow and 3) NIPPV (Infant Flow SiPAP). For Infant Flow there 
was an increase in tidal volumes and a reduction in respiratory rate when increasing CPAP 
from 5 to 7 (or 9) which was not seen in the bubble CPAP. Apart from the differences in tidal 
volume at higher CPAP levels there were no other significant differences between the 
devices.  
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In summary, trials with cross-over methodology and short term physiological outcomes show 
changes in breathing parameters that could be related to imposed work of breathing and 
pressure stability. The most consistent finding is increased tidal volumes and reduced 
respiratory rate for pressure stable systems like Infant Flow. In most studies, but not all (for 
example Lipsten), these effects increase at higher CPAP. The trials that determine work of 
breathing (Courtney, Habib et al. group) show increased work of breathing with less pressure 
stable systems. The clinical relevance of increased tidal volumes and reduced respiratory rate 
is not known. For instance, Huckstad interpret this as improved ventilation and Pickerd as 
potentially disadvantageous.83,85 
There were no results in these trials that contradict pressure stability as a factor that affects 
breathing parameters, but some system comparisons show little or no difference. The authors 
mention several explanations when differences could not be found: 1) The difference between 
the systems were not large enough or 2) the infants were not small or sick enough.80,81 The 
trials included relatively few patients and most variables had large variability (high variance). 
This could be because of a heterogeneous patient population, method related or due to a high 
natural variance.  
2.4.4.2 Randomised controlled trials with clinical outcomes 
 
NCPAP after extubation  
Two trials frequently referred to were only published as abstracts (American Pediatric 
Society meeting 1999). Sun and Tien performed an RCT on 73 infants post extubation 
comparing Infant Flow to conventional NCPAP (Medicorps interface, not short binasal).88 
They showed less extubation failure in the Infant Flow group (16% vs 54%). Roukema 
performed an RCT on infants post extubation comparing Infant Flow to nasopharyngeal 
CPAP.89 The failure rate was lower in the Infant Flow group (18/48 vs 27/45). 
Davis (2001) performed an RCT comparing single prong (2,5 cm inserted Portex tube) to 
short binasal prongs (Hudson) after extubation in 87 infants at 26 weeks of gestation.90 CPAP 
was provided by a ventilator (manufacturer not stated). Lower failure rate was seen with 
binasal (24%) compared to single-nasal prongs (57%). 
Stefanescu (2003) performed an RCT comparing Infant Flow to a ventilator connected by 
INCA prongs after extubation in 162 infants <1000 g.91 There were no differences in 
successful extubation (61,7%), death, BPD or time on CPAP. The Infant Flow group showed 
shorter hospital stay and fewer days on supplemental oxygen. The authors note that the 
ventilator CPAP group was slightly heavier and older than the Infant Flow group (not 
significant). 
Gaupta (2009) performed an RCT of post-extubation support comparing bubble CPAP to 
Infant Flow.92 They randomised 140 infants (approximately 27 weeks of gestation (1,07 kg)). 
There were no differences in the primary outcome of extubation failure (27,5% Infant Flow 
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and 16,9% bubble CPAP) for the whole population. In a subgroup analysis of infants <14 
days on ventilator, there was a difference in favour of bubble CPAP. Reduced duration of 
CPAP treatment was seen in bubble CPAP but not after including infants who died in the 
analysis. 
NCPAP after birth 
Mazzella (2001) performed an RCT comparing Infant Flow to single pharyngeal prong 
interface (bubble CPAP) in 36 infants.93 Patients were <36 weeks of gestation and those who 
had received antenatal steroids were excluded. Treatment was started at a median age of six 
and seven hours for the pharyngeal prong and Infant Flow respectively. There were lower 
oxygen requirements and lower respiratory rates in the Infant Flow group. There was no 
difference in the number of infants who failed on NCPAP (five on nasopharyngeal tube and 
one on Infant Flow). 
NCPAP after birth and after extubation 
Bober (2012) performed an RCT comparing Infant Flow to the ventilator Babylog 8000 
(Hudson prongs) in 276 infants (approximately 28 weeks GA and 1,1 kg) who were started 
on NCPAP <6 h after birth (n=119 elective group) or after extubation (n=157 weaning 
group).94 The main outcome was failure on NCPAP (intubation or reintubation). The trial was 
stopped early because of nasal injuries in the ventilator (Hudson prongs) group. There was a 
non-significant trend towards less failure in the weaning group for the Infant flow system but 
no difference in the elective group. The safety outcomes showed that the infant flow group 
had more pneumothoraces and the ventilator group had more necrotising enterocolitis and 
severe nasal injuries. 
Summary of randomised trails with clinical outcome 
In summary the RCTs comparing NCPAP systems or interfaces show conflicting results. This 
has been noted in several reviews and, apart from recommending short binasal prongs, 
reviews do not guide the users as to which systems to use.3,22 The importance or non-
importance of pressure stability as a factor affecting outcome cannot be judged from the 
randomised controlled trials. Pragmatic trials reveal important clinical outcomes other than 
NCPAP failure. For instance, the trial by Bober had 17,8% (24 of 135 patients) severe nasal 
injuries in the ventilator (Hudson prongs) group.  
2.4.5 Summary 
An array of systems for CPAP generation and patient interfaces are available. Data on 
differences in performance and pressure stability have been published, but the clinical 
importance remains uncertain. There are no hard data on the importance of providing 
pressure stable CPAP or using systems with low imposed WOB even if physiological 
reasoning and expert opinion suggest that this may be an important factor for avoiding 
mechanical ventilation and failure on CPAP.  
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2.5 MEASURING AIRWAY FLOWS IN INFANTS 
The measurement of airway flow is used for basic description of tidal breathing parameters to 
complete infant pulmonary function testing. There is a need to standardise technology and 
measurement techniques to allow data from different centres to be pooled or compared.95,96 
In adults the technology for measuring airway flow is widespread but its use in neonates is 
limited mainly because of the following technical challenges:  
• rapid respiratory rate and small tidal volumes 
• low tolerance for increased resistance  
• low tolerance for adding dead space 
• sensitivity to airway manipulation and problems with leakage at interface 
• low tolerance for adding bulky equipment close to the patient 
The most commonly used approach is to measure airway flow directly by using a patient 
interface attached to the flow-meter equipment. The European Respiratory Society/American 
Thoracic Society (ERS/ATS) Task Force document is limited to these direct measurements.95 
Indirect techniques do not rely on direct flow measurement and are described by the task 
force as difficult to standardise.  
A potential advantage of indirect measurements is that they avoid problems with airway 
manipulation, leakage, resistance and dead space. Examples of techniques that measure flow 
indirectly are face-out body plethysmography and respiratory inductive plethysmography 
(band plethysmography).97 New techniques such as electrical impedance tomography, 
electromagnetic inductive plethysmography and optoelectronic plethysmography have 
recently been developed.98-100 These are mainly research tools and have limited use in the 
clinical setting.101 
Measuring flow during NCPAP with a direct technique would be a useful tool for further 
studies on the importance of imposed WOB and the effects of NCPAP. 
 
2.5.1 Measuring airway flows without CPAP 
Airway flow can be measured at two positions in respiratory support systems or circuits (Fig. 
3). Flow measurement can be either between the patient interface and the respiratory support 
system (in-line) or on the expiratory limb (flow-through).  
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Figure 3: In-line and flow-through position of the flow meters. The in-line position adds 
dead-space. The flow-through position does not add dead-space if the bias flow is sufficient. 
The flow-through position is technically more challenging since the bias flow has to be 
subtracted to measure breathing. Figure from Paper III.  
The advantage of the in-line position is that it is technically simple and insensitive to the 
compliance and resistance of the circuit (or NCPAP system). The disadvantage is that the 
volume inside the flow meter will add extra dead-space and rebreathing. To minimise dead 
space, the internal volume has to be small and the flow meter be placed as close to the patient 
as possible. Most variable-flow NCPAP systems do not allow fitting of a flow meter between 
the NCPAP generator and the patient interface because of their small size and integrated 
prongs. 
The advantage of the flow-through position is that it will not add dead-space since it is 
positioned on the expiratory side (limb). The bias flow prevents rebreathing by constantly 
washing out the CO2. The disadvantage is that it is technically more difficult since the bias 
flow has to be subtracted, and the tube compliance and resistance of the circuit or NCPAP 
system will affect measurements. 
The first measurements of lung function in newborn infants were performed many years 
before the development of NCPAP. In 1956, Berglund and Karlberg used a face mask and 
helium dilution to determine functional residual capacity. Volumes were determined by 
spirometers.44 The problems with resistance and adding dead-space seem well-recognised at 
the time. As an example of this, in 1966 Silverman presented resistance (static flow 
comparisons) and dead-space volumes (0,4 to 0,9 mL) for four devices.47 They solved the 
problem of rebreathing by using valves or non-rebreathing anaesthetic circuits. 
The problem of rebreathing and resistance is still a concern. Systems with high resistance and 
large dead-space are still in use. An example is the use of flow meters (in-line position) with 
CPAP by T-piece resuscitation devices.102 When used with spontaneous breathing, both the 
dead-space and resistance for these devices are high compared to what was state-of-the-art 
more than 50 years ago for measurements without CPAP.47 
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The first measurement of airway flow using flow-through technique in preterm infants was in 
1972 by Brady and Rigatto.103 They developed and tested a flow-through system that had low 
dead space (0,06 mL) and low resistance (Fig. 4). They describe the relation between 
resistance and dead space for in-line measurement as "if dead-space is kept at a minimum, 
resistance tends to be high, and if resistance is kept at a minimum, dead-space tends to be 
large. In both instances minute ventilation and the work of breathing are increased". They 
report the use of their new flow-through system in 40 preterm infants (1-2 kg).  
 
 
Figure 4: Flow-trough system used by Rigatto and Brady: "Nosepiece used with a constant 
background flow of gas to measure ventilation in preterm infants. To body of nosepiece, a 
segment of the barrel of a 5-ml syringe, we added a Monel screen (resistance element), two 
nostril adapters, and a removable gas connector".103 
The system was used a few years later by Lahiri in an investigation of infants born at high 
altitude.104 They measured the ventilatory response to changes in oxygen concentration of 
newborn infants at 3850 m (Puno) and 800 m (Tacna) in Peru.  
In 1981 Ruttimann further developed the Rigatto system by adding a second 
pneumotachograph on the inspiratory tubing.105 This allows for compensation when 1) fresh-
gas flow varies or 2) in measurements where pressure variations and tube compliance affect 
measurement (as in mechanical ventilation or pressure-unstable CPAP). They investigated in-
vitro performance and tested the system in intubated rabbits. 
In 1983 Thomsson used a similar double pneumotachograph system to investigate lung 
compliance in spontaneously breathing intubated preterm infants (mean weight 1200 g).106 
Their main finding was that a simplified method of oesophageal balloon catheters recordings, 
used to estimate compliance, did not give correct estimates in sick infants. In the healthy 
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control infants, they did not use the double pneumotachograph system, but a standard in-line 
measurement. 
None of these studies used flow-through technique in combination with non-invasive CPAP 
in spontaneously breathing infants. 
2.5.2 Measuring airway flow during CPAP 
The first reported use of flow-through measurements and CPAP was in 1988 by 
Andreasson.107 They investigated lung mechanics after extubation in premature infants and 
used a face chamber with flow-through technique (constant bias flow of 7 L/min). A similar 
interface had been used earlier but the CPAP generator was modified with addition of a high-
flow fan dedicated to feeding the resistor.108,109 
The only use of flow-through measurements in combination with a variable flow NCPAP 
generator (Infant Flow with nasal prongs) were by Huckstadt in 2003.83 They performed a 
randomised cross-over comparison of Infant Flow (short bi-nasal prongs) and Babylog 8000 
(single cut ET-tube, other nostril occluded). 46 of 69 infants had to be excluded because of 
air leaks in one or both recordings (33 for Babylog and 37 for Infant Flow). Three more 
infants were excluded because of apnoea (n=1) and irregular breathing (n=2). For the 
remaining twenty infants they concluded that Infant Flow improved ventilation with less 
pressure swings, increased peak flows and increased TV. 
The Huckstadt group have published work on the flow-through technique since 1995.110,111 
The first description in English is from 1998 with a detailed study on the effect of leakage on 
measurements.112 After the problems with leakage in the Huckstadt manuscript (2003) they 
seem to have discontinued the work on the flow-through technique and in their publications 
from 2008-2009 in-line measurements are used instead.113-115 
2.5.3 Summary 
Measuring airway flow with the flow-through technique can achieve almost dead-space free 
measurements and has been used with CPAP by two groups. Andreasson used a face 
chamber and Huckstadt nasal prongs.83,107 Reliable measurement of flow seems possible but 
leakage is a major problem with the prong interface. 
 
2.6 RESUSCITATION OF THE NEWBORN INFANT 
2.6.1 Transition to breathing and resuscitation 
In the first minutes after being born, the infant goes from having full placental support to 
managing breathing and gas exchange on its own. The physiological changes during this 
transition are dramatic. Air breathing requires the lungs to be cleared of fluid and gradually 
expand. The surfactant secreted by the Type II pneumocytes facilitates the increase in FRC 
by reducing surface tension and increasing compliance. The cardiovascular system switches 
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from foetal circulation, where the ventricles work in parallel, to a circulation where they work 
in series.116,117 
In term infants, 85% start to breathe unaided and 10% require stimulation. Respiratory 
support is needed for the last 5%, out of which 3% will breathe after PPV and 2% need to be 
intubated.21 The number of infants who need support is higher in preterm and extremely 
preterm infants. 
Failure to breathe and establish FRC is an emergency that requires immediate attention. 
Managing ventilation is the first priority in all resuscitation guidelines.  
 
2.6.2 Premature infants and non-invasive support 
2.6.2.1 Systems for PPV and CPAP 
CPAP during resuscitation has been suggested to be advantageous. The reasons are the same 
as when it is given to an infant in respiratory distress (section 2.1 Effects of NCPAP). Infants 
who do not breathe, or have inadequate breathing, need ventilation with PPV. This is not 
possible with standard NCPAP systems. The three techniques available for PPV are T-piece 
resuscitators, self-inflating bags or flow-inflating bag systems.118 The flow-inflating bag is 
considered to required more experience to handle.119 
The T-piece systems can be designed to provide CPAP and bag systems can be equipped with 
a CPAP valve. However, for at least some bag and CPAP valve systems, PPV needs to be 
given at a high rate in order to deliver PEEP and the systems cannot generate CPAP during 
spontaneous breathing.118,120 
When providing guidelines or conducting research, the use of different devices and interfaces 
for CPAP support complicates interpretation. The ILCOR consensus document recognises 
this problem: "Interpretation of human studies is further complicated by varying interfaces 
(eg, face mask versus endotracheal tube) and methods of generating PEEP (eg, self-inflating 
bags with PEEP valve versus T-piece resuscitator)".21 
Regarding the use of CPAP during resuscitation the ILCOR consensus "suggest using PEEP 
ventilation for premature newborns during delivery room resuscitation (weak 
recommendation, low-quality evidence)". ILCOR could not make any recommendations for 
term infants.21  
 
2.6.2.2 Interface during resuscitation 
Short bi-nasal prongs are recommended for NCPAP but there are few publications using bi-
nasal prongs during resuscitation.3 The clinically most commonly used interface is the face 
mask.  
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Short bi-nasal prongs for resuscitation were first used by Capasso in 2005.121 They compared 
Argyle prongs to a face mask in 617 infants who needed PPV. Interfaces were used with a 
self-inflating bag and no CPAP in mainly term infants. Patients ventilated with prongs had 
fewer intubations (0,6% vs 6,4%), less chest compressions, deaths and neonatal intensive care 
unit (NICU) admissions. They have been criticised for the use of a triangular shaped face 
mask (Redell-Baker) rarely used in other centres.122  
Lamberska presented an abstract of a cohort study of prongs during resuscitation and a 
comparison to historical controls.123 
Paz presented a single-centre clinical experience from patients using bi-nasal RAM-cannulas 
with a T-piece resuscitator.124 They acknowledge a weak study design and conflict of 
interests.  
There are more publications using a unilateral nasal tube (pharyngeal, cut ET-tube). Kamlin 
performed an RCT of 363 infants born at 24-29 weeks of gestation.125 They compared a cut 
ET-tube (size not mentioned, inserted 3-4 cm) to a face mask connected to a T-piece 
resuscitator. There were no differences in intubation rates (54% and 55%) and the trial was 
stopped early because of futility. To minimise leakage, they occluded the mouth and 
contralateral nostril.  
McCarthy also compared a unilateral nasal tube (5 cm cut ET-tube, size 2.5 to 3.0) to a face 
mask connected to a T-piece resuscitator.126 The RCT included 144 infants (<29 weeks of 
gestation) and there was no difference in intubation rates (15% in both groups).  
 
2.6.2.3 Human RCTs of PPV and CPAP 
The ILCOR consensus document recognises the weak evidence for recommending T-piece in 
favour of bag systems during resuscitation.21 Reliable (but not pressure stable) CPAP can 
only be provided with T-piece systems. The bag systems cannot maintain CPAP when the 
infant starts to breathe or provide reliable PEEP during PPV.120 The ILCOR consensus 
document refers to two RCTs when recommending T-piece systems:  
Dawson investigated PPV delivered by T-piece or a self-inflating bag (no CPAP) in an RCT 
of 80 infants (<29 weeks of gestation).127 They showed no difference in primary outcome of 
oxygenation at 5 minutes.  
Szyld performed a cluster randomised controlled trial comparing T-piece to a self-inflating 
bag (with a PEEP valve in six out of 11 participating centres) in infants >26 weeks of 
gestation.128 195 patients were VLBW (<1500 g) and the distribution of these were uneven 
with more VLBW infants in the self-inflating bag group. They were not able to detect any 
difference in their primary outcome of the proportion of patients with a heart rate above 100 
at two minutes. Secondary outcomes showed that the T-piece patients had fewer intubations 
and lower delivered maximum positive inspiration pressure.  
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3 AIMS 
The overall aim of this thesis is to understand and improve neonatal NCPAP respiratory 
support. This includes investigations of existing techniques for respiratory management as 
well as development of new respiratory support systems for research and clinical use in this 
field. 
 
The specific aims of the included studies were: 
• To compare existing systems used for NCPAP care using simulated neonatal 
breathing and determine imposed work of breathing (Paper I and II) 
• To evaluate systems and techniques used for measurements of neonatal breathing 
focusing on the in-line versus the flow-through position and its effects on imposed 
work of breathing in a mechanical lung model (Paper III) 
• To	develop a system for respiratory support during neonatal resuscitation and test this 
device in a clinical feasibility trial on preterm infants (Paper IV) 
 
4 METHODS 
 
4.1 MECHANICAL LUNG SIMULATION (PAPER I-IV) 
4.1.1 Methods, introduction and comment 
The pressure stability of NCPAP support can be measured by mechanical reproduction of 
breathing. These mechanical lung models are standard tools used by manufacturers of 
ventilators and researchers interested in respiratory support systems. The main advantages of 
mechanical lung models, compared to animal or human studies, are high reproducibility with 
low variability, low costs and uncomplicated ethics. The main disadvantage is that the tests 
are performed in an artificial setting and have limited clinical value. 
Imposed work of breathing is the added work needed to breathe through a device. This can be 
illustrated by the shape of a pressure-volume loop for a spontaneously breathing infant or in 
the simulated breathing of a mechanical lung model. Examples of alternative variables to 
describe pressure stability are direct measurements of pressure changes during the breathing 
cycle or pressure time product (section 2.4.2.3). 
. 
  27 
4.1.2 Technical description 
4.1.2.1 Breathing profiles 
The method used in all papers include a mechanical lung model (ASL 5000 from IngMar 
Medical, Pittsburg, USA) that can reproduce flow patterns. The mechanical lung model was 
used in flow-volume mode. This reproduced a series of identical breaths without simulated 
compliance or resistance.  
The breath profiles used in Paper I and II were from two separate infants. The flow 
recordings from the term infant (3,4 kg) were from the manuscript by Moa and the preterm 
infant recordings were obtained from medical records (routine dynamic spirometry recording 
during quiet sleep in a 1,3 kg infant).64 In Paper III and IV, symmetrical sinusoidal flow 
patterns were used. 
4.1.2.2 Experimental set-up 
The CPAP system, with or without interface, was attached to the lung simulator using a 
standard 22 mm connector. Adhesive putty was used for airtight fixation. The CPAP level 
was adjusted before simulation was started.  
Leakage was generated by applying a constant leak between the system and the lung 
simulator (at the 22 mm connector). Use of variable leakage was not attempted since it does 
not allow for identical test conditions.  
4.1.2.3 Data collection and software 
The mechanical lung model is a piston pump that measures volume (using the position of the 
pump) and pressure (in the piston chamber). The volume is corrected for gas compression in 
the piston chamber but not for volume or compliance outside the mechanical lung model. The 
accuracy of the mechanical lung volume variables was confirmed by fixed volume syringes 
and calibrated flow-pressure measurement equipment (VT PLUS HF from Fluke Biomedical, 
Everett, USA).  
Imposed work of breathing was calculated by integrating the area within the pressure-volume 
loop for a single breath.71 This variable was not calculated in the standard software and the 
manufacturer provided a modification for this purpose. Manual calculation of loop area was 
used to confirm that the software integration was correct.  
The data were recorded and processed by the modified software. The software saved data on 
individual breaths and these could be compiled for further analysis. The main variables used 
in papers I-IV were delivered pressure, pressure fluctuations (maximum, minimum and total 
amplitude of swings) and imposed work of breathing. 
4.1.2.4 Processing data after collection 
Data from the series of experiments were compiled in Excel and exported to SPSS for further 
analysis. Pressure-volume loops were exported directly from the ASL software.  
 28 
4.1.2.5 Statistical analysis 
Statistical comparisons of means were performed using ANOVA with correction for multiple 
comparisons. The variability in the measurements was generally low and statistical 
comparisons identified differences that were small and not likely to be clinically relevant. A p 
value of less than 0.05 was considered statistically significant. 
 
4.2 RECORDING FLOW (PAPER III) 
4.2.1 Introduction and comment 
Flow recordings should ideally be performed with systems that have low dead space and low 
resistance in combination with high signal quality. Resistance can be measured using a 
mechanical lung model and the in-vitro dead space can be estimated by measuring volumes 
that contribute to rebreathing. 
Determining the quality of the flow signal is more complex since the overall signal quality 
will depend on several components. Ideally, these components should be optimised for the 
task. Detailed testing of signal quality would therefore require in-depth knowledge about 
signal processing and analysis as well as the individual components used in a system. This 
was beyond the scope of the manuscript. Instead, simple graphical presentations of the raw 
signals were used to estimate quality. The main problem with this approach is that the signals 
represent various degrees of post-collection processing and components have not been 
optimised for the tested flow range 
4.2.2 Technical description 
4.2.2.1 Experimental set-up 
The flow meters were connected to the mechanical lung simulator using the in-line or the 
flow-through position (Fig. 5). The flow-through position was also tested in combination with 
an Infant Flow CPAP generator. The lung simulator reproduced a symmetrical sinusoidal 
flow pattern in the experiments. Resistance was recorded using the mechanical lung simulator 
described above (4.1). 
4.2.2.2 Collecting and presenting flow data 
Flow data were collected using provided hardware and software when available. A digital 
acquisition system (DAQ system) was used for flow meters with an analogue output. The raw 
flow data recording of a single breath was exported to Excel and presented graphically. There 
was no statistical analysis performed on the data obtained from the flow meters. 
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Figure 5: In-line and flow-through position. The bias flow experiments (top) were performed 
to measure pressure stability and imposed WOB with in-line and flow-through position. A 
bias flow of 0 L/min is equivalent to in-line positioning. The variable flow CPAP generator 
experiments (bottom) were performed with an Infant Flow variable flow NCPAP generator. 
Figure from Paper III. 
 
4.3 DEVELOPING A NEW SYSTEM FOR RESUSCITATION (PAPER IV) 
4.3.1 Introduction and comment 
The first manuscript (Paper I) identified the Neopuff system as being pressure unstable. This 
is a general characteristic of CPAP systems that use resistance to generate CPAP. A new 
system, based on the same principles as the original Infant Flow, was developed. The aim 
was to allow PPV in a similar way to T-piece systems but also to improve pressure stability 
during spontaneous breathing. The system should also be possible to use with either face 
mask or nasal prongs. The designed system was evaluated in-vitro.  
The final prototypes were produced by the research group and evaluated in a small clinical 
feasibility trial on initial stabilisation of preterm infants. 
4.3.2 Design, testing and production 
4.3.2.1 Design and testing 
Prototypes were designed using solid modelling computer-aided design (3D CAD) software 
and three dimensional (3D) printing. This development and manufacturing technique is often 
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referred to as rapid prototyping. The prototypes were tested in the mechanical lung model to 
measure pressure stability during simulated spontaneous breathing. The mechanical lung 
model testing was described in section 4.1. The design was revised several times to optimise 
pressure stability and functionality. Figure 6 displays a selection of prototypes and figure 7 
gives a description of the new system. 
 
 
Figure 6: Selected 3D printed prototypes. Far left prototype (2011) represent an early version 
with a connector intended for face mask interface or endotracheal tube. The next three 
revisions include a connector for nasal prongs. The last prototype (2014) can be used with 
nasal prongs or, by changing the connector close to the patient, a face mask (not shown). 
 
Figure 7: Description of the new system. Left: The outlet (A) is open during spontaneous 
breathing. The patient interface is either short bi-nasal prongs (B) or a face mask (not shown, 
change of connector (C) required). Middle: Continuous positive airway pressure (CPAP) is 
mainly generated by the flow in the small diameter line (green arrow) by the same method as 
described by Moa et al. The turbulent flow (green) in the angulated tube (purple) opposes 
expiration and supports inspiration (white arrow). Right: The bias flow (blue) is pressure 
limited (valve and pressure port positioned upstream) and occlusion of the outlet will 
generate an inspiratory flow (white arrow). Expiration with positive end expiratory pressure 
(PEEP) is identical to expiration during CPAP (middle). Figure from Paper IV (in press). 
  31 
4.3.2.2 Safety 
The systems used in the feasibility trial were assembled from standard medical parts and the 
resuscitation systems were produced in a medical graded material. A risk analysis was 
performed together with the Medical Technology department at Östersund Hospital, Sweden. 
The systems were used as in-house produced medical equipment. The use was limited to the 
Karolinska University Hospital, Sweden and the ethically reviewed feasibility trial.  
Producing systems for larger trials is more complex. In Sweden, these trials require a CE-
marked product or a clinical trial registered at the Medical Products Agency (both have 
similar regulatory requirements and standards regarding production and testing). 
Manufacturing of systems by academic research groups for use in larger trials is generally not 
feasible (CE-marked or equivalent standard). 
4.3.3 Clinical feasibility trial 
4.3.3.1 Patient selection and sample size 
The patient population represented a convenience selection and the results from the trial were 
not intended to reflect a defined patient population. 
Infants delivered at 27-34 weeks of gestation were selected since they often require 
respiratory support. A population with term infants would have been difficult to include since 
they rarely need respiratory support and consent had to be obtained before delivery. A 
population of smaller infants, for instance extremely premature infants, is generally not 
suitable for feasibility trials. The patients were recruited from two units of the Neonatal 
department at the Karolinska University Hospital.  
The trial was not intended to detect treatment effects and no power calculations were 
performed. 
4.3.3.2 Inclusion and randomisation 
Parents who were admitted for threatening preterm delivery were approached. The inclusion 
criterion was preterm birth (27-34 weeks of gestation) and exclusion criteria included cardiac 
or airway malformations, syndromes and neuromuscular disease.  
After consent, the infant was randomised by sealed opaque envelopes when birth was 
imminent. If the infant did not require respiratory support, the envelope was recycled. 36 
patients were included with 12 infants in each arm. Randomisation was in one block (12*3) 
and not stratified.  
4.3.3.3 Intervention 
After birth, the infant was supported using the randomised system for 10-30 minutes. The 
three treatment arms were 1) standard T-piece resuscitator, 2) the new system with face mask 
and 3) the new system with short bi-nasal prongs. Infants who required respiratory support 
 32 
received 4 cm CPAP and 20 cm H2O PPV if needed. Treatment was provided according to 
the ILCOR consensus document 129 and national guidelines130. 
4.3.3.4 Outcomes and variables 
The outcomes were related to 1) stabilisation and use of respiratory support in the delivery 
room, 2) respiratory support and use of surfactant within the first 72 hours and 3) safety. Data 
from the delivery room were collected after initial stabilisation and the medical records were 
reviewed after 72 hours. Variables included delivery room intubations, use of PPV, oxygen 
demand, APGAR, and peripheral capillary oxygen saturation (SpO2). The 72-hour review of 
medical records collected data on the use of surfactant, intubation and mechanical ventilation. 
Safety variables included pneumothorax and problems with equipment or its usage. 
4.3.3.5 Statistical analysis 
For all variables the distribution of data were tested for normality with Shapiro-Wilk tests and 
presented as mean (SD) or median (interquartile range). Differences were tested with 
ANOVA or Kruskal-Wallis tests. Nominal data were tested with Fisher's exact test. 
 
5 RESULTS 
 
5.1 PERFORMANCE OF NCPAP (PAPER I AND II) 
 
5.1.1 Example of differences in pressure stability 
The CPAP systems tested in the mechanical lung model showed large variations in pressure 
stability. An example of the recorded differences imposed work of breathing is presented in 
figure 8 (including reprocessed data from paper I and II). Statistical comparisons of variables 
(means generated from consecutive breaths) from simulations in the mechanical lung model 
were statistically significant at levels below what is likely to be of clinical significance (eg 
Airlife and Infant Flow LP (figure 8)). Examples of pressure-volume loops for some systems 
are presented in figure 9 where low-imposed WOB devices (eg Infant Flow) have narrow 
loops and high-imposed WOB devices have wide loops (eg Medijet and Neopuff).  
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Figure 8: Imposed WOB at 4 cm CPAP for 15 consecutive breaths. Breath profile from a 
healthy 3,4 kg infant. All systems were tested with large prongs except Neopuff that was 
tested without prongs. Infant Flow LP has a different design to Infant Flow but almost 
identical to Airlife. All differences were statistically significant except Fabian and Infant 
Flow LP (marked *). Data partly presented in Paper I and II. 
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Figure 9: Examples of pressure-volume loops from CPAP systems at 4-5 cm H2O CPAP. 
Loops recorded for a single, simulated breath from a 3,4 kg healthy infant and large prongs 
(Neopuff tested without prongs). The SERVO-i and the VN500 have a small level of pressure 
support and do not only provide CPAP. The right four loops in top row from Paper II. 
 
5.2 MEASURING FLOW (PAPER III) 
The results show the effects of flow meter resistance with the flow meter positioned in the in-
line or flow-through position (Fig. 10). With increasing resistance, there is an increased 
imposed WOB and CPAP generation (in the flow-through experiments). The flow meters 
intended for neonatal use had higher resistance and larger effects on imposed WOB and 
CPAP. The flow meters with low resistance showed smaller effects on imposed WOB but 
instead had large dead space volumes. 
In experiments where the flow meter was connected to the exhaust of an Infant Flow CPAP 
generator the results were similar. Increased imposed WOB was seen in devices with higher 
resistance (Fig. 11, statistical significant differences for Fleisch 0, FLORIAN and 
EXHALYZER S in all comparisons). 
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Figure 10: Imposed WOB (Total iWOB) at three levels of bias flow for six flow meters. A 
bias flow of 0 L/min is equivalent to positioning the flow meter in-line. Bars indicate mean 
imposed work of breathing (with 95% CI) for 20 consecutive simulated breaths (TV 32 mL, 
respiratory rate 60 and inspiratory expiratory ratio (I:E) 1:1). All differences between the flow 
meters were statistically significant except SFM3200 prototype and Vitalograph Fleisch at 10 
L/min. Figure from Paper III. 
 
Figure 11: Imposed WOB (Total iWOB) for six flow meters at three levels of CPAP. The 
flow metes were connected to an Infant Flow CPAP generator using flow through position. 
Bars indicate mean imposed work of breathing (with 95% CI) for 20 consecutive simulated 
breaths (TV 32 mL, respiratory rate 60 and I:E 1:1). Statistical significant differences were 
found in all simulations with Fleisch 0, FLORIAN and EXHALYZER S, but not in all 
simulations with SpiroQuant A, SFM3200 prototype and Vitalograph Fleisch. Figure from 
Paper III. 
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The graphical display of the recorded flow data showed that at least two devices with low 
resistance may be used with NCPAP systems in combination with flow-through 
measurements (SFM3200 prototype and Vitalograph Fleisch, figure included in Paper III). 
 
5.3 A NEW RESUSCITATION SYSTEM (PAPER IV) 
5.3.1 Design and in-vitro performance 
The design and use with prongs on a manikin is shown in figure 12. In simulated neonatal 
breathing, the new resuscitation device showed a marked reduction in imposed WOB and an 
increase in pressure stability compared to T-piece resuscitation systems (Fig. 13, statistical 
significant differences in all comparisons with T-piece systems).  
 
Figure 12: The new system with nasal prongs used on a manikin. Delivery of CPAP and 
PPV would require minimising leakage by closing the mouth of the manikin. PPV can be 
obtained by occluding the outlet port (marked with arrow). 
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Figure 13: Imposed work of breathing (mean and 95% CI) for T-piece systems and the new 
system at increasing levels of CPAP in simulated breathing (TV 32 mL, respiratory rate 60 
and I:E 1:1). Statistical significant differences at all levels of CPAP for comparisons between 
new system with face mask, new system with prongs and T-piece systems (no difference 
between GE and Neopuff at 3, 4, 6, 8 and 9 cm H2O). Figure from Paper IV (in press). 
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5.3.2 Clinical feasibility trial 
Informed consent was obtained for 45 patients out of which 39 were included in the study. Of 
these, 36 needed respiratory support and were randomised into three arms of equal size. The 
randomisation resulted in unbalanced groups with significant differences in gestational age. A 
larger proportion of these more immature infants were treated with surfactant (statistically 
significant). There were no other statistically significant differences in outcome or treatment 
between the groups (Table 2). 
Two patients treated with the new system (with prongs) developed pneumothoraces in the 
NICU. They are reported in detail in the manuscript but judged not to be related to 
resuscitation. One patient could not be ventilated with the new system. Changing to T-piece 
system did not improve ventilation and the infant had to be intubated. There were no other 
safety concerns or problems with the equipment. 
 T-piece New System  
Interface Face Mask Face Mask Nasal Prongs  
Number of infants 12 12 12  
Gestational Agea 33+0 
231 (9.9) 
32+4 
228 (10.7) 
30+5  
215 (16.9) 
0.009 
Weight (g) 1828 (1611-2487) 1529 (1308-1829) 1508 (1125-2042) 0.06 
Sex (Female/Male) 6/6 6/6 5/7 1.00 
Vaginal delivery 5 4 2 0.54 
Steroids complete b 7 3 7 0.30 
Positive Pressure 
Ventilation 
5 6 2 0.34 
Intubated in delivery 
room 
0 0 1 1.00 
APGAR 1 min 9 (8-9) 9 (6-9) 9.0 (8-9) 0.99 
APGAR 5 min 9 (8-9) 10 (8-10) 9.0 (9-10) 0.43 
APGAR 10 min 10.0 (9-10) 10.0 (10-10) 10.0 (10-10) 0.15 
Time to regular 
breathing (min) 
1.0 (0.0-5.0) 0.5 (0.0-5.0) 0.0 (0.0-1.0) 0.57 
Time to SpO2 90% 9.0 (6.0-10.0) 9.0 (5.5-10.0)c 6.0 (3.8-6.8) 0.33 
Received surfactant 
<72h 
2 0 5 0.046 
Pneumothorax 0 0 2 0.31 
 
Table 2: Summary of the three treatment groups. Values as median with interquartile range 
except Gestational Age (mean).a First row mean in weeks+days and second row mean (SD) in 
days. b Two doses with at least 24 h from first dose to delivery and second dose at least 12 h after 
first dose. c Two missing (n=10). Table from Paper IV (in press). 
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6 GENERAL DISCUSSION 
6.1 PERFORMANCE OF NCPAP SYSTEMS 
The mechanical lung model allows detailed measurements of performance. Large differences 
(statistically significant) between CPAP systems were identified. The in-vitro tests show that 
when discussing pressure stability, it is not possible to make generalised statements on 
performance of variable flow NCPAP or NCPAP delivered by ventilators. Bubble CPAP and 
the resistor systems (represented by T-piece) should have a more predictable performance.  
The inexpensive bubble CPAP was more pressure stable than some expensive ventilators. 
Three ventilators were not only providing CPAP but also a low level of pressure support. An 
example is the SERVO-i ventilator which has a narrow pressure-volume loop indicating high 
pressure stability but the small pressure support does not allow calculation of imposed WOB. 
Resistor systems, represented by the T-piece system, are pressure unstable when used with 
fresh-gas flow in the same range as inspiratory and expiratory flows. They were used by 
Gregory but then abandoned for the more pressure stable bubble CPAP. 
The Medijet NCPAP system had the highest imposed WOB of all tested systems. It has been 
presented as an improved Benveniste valve but the high imposed WOB is related to the 
CPAP being generated by resistance (data not published, manuscript in preparation and not 
included in the thesis). This gives a performance similar to the T-piece systems. 
A limitation of the in-vitro tests is the fixed breathing pattern. In real infants the breathing 
pattern is likely to adapt to changes in imposed work of breathing, CPAP level and leakage. It 
is not possible to allow the mechanical lung model to simulate these adaptions since it would 
give measurements that do not allow comparison of imposed WOB between systems.  
The constant leakage used in the simulations is far from the clinical reality. Leakage in 
patients will vary with prong size, prong design, CPAP level, breathing pattern, level of 
mouth leakage and the pressure stability of the system being used. Leakage will at the same 
time also affect the delivered CPAP level and the pressure stability. These multiple 
interactions will give simulations that are too complex to allow comparisons of different 
systems. Leakage is probably an important factor in trials of NCPAP and interfaces. For 
instance, Huckstadt had major problems with leakage and 46 out of 69 recordings had to be 
excluded.83 
The in-vitro tests showed large differences in pressure stability between different CPAP 
systems. The clinical importance of this is not known. If pressure stability is of importance, it 
raises several questions. It would be difficult to generalise results from a trial that uses a 
particular system or a mix of systems with varying pressure stability. It would also question 
conclusions from pooled data from CPAP trails in meta-analyses. This problem with 
generalisation of results is present in all clinical trials and not unique for NCPAP.  
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Investigations on effects of increased CPAP is an area where the presented results may be 
important. Some systems (eg T-piece system) show a steep increase in imposed WOB with 
higher CPAP. These systems do not permit isolated testing of effects of increasing CPAP 
since this will increase imposed WOB at the same time. The insufficiently studied clinical 
effects of differences in pressure stability remain to be investigated. 
 
6.2 MEASURING FLOW 
The flow-through technique has been used in several studies. The original study by Rigatto 
was without CPAP.103 When the flow-through technique is used in CPAP or respiratory 
circuits with pressure swings, the effects of tube compliance and gas compression need to be 
controlled. The flow-through technique is therefore more complicated to use than the in-line 
technique during positive pressure ventilation (large pressure changes) or pressure unstable 
CPAP. The CPAP also increases leakage. Huckstadt had to exclude a majority of their 
included patients because of problems with leakage.83 
The main disadvantages of positioning a flow meter in-line are the addition of dead space and 
the added bulk. It has been used for short periods of time and during resuscitation. In 
resuscitation, the focus has mainly been to identify leakage, airway obstruction and TV 
during PPV.131 The added dead-space is a clinical concern in situations with no leakage and 
with longer duration of use. Rebreathing could affect carbon dioxide levels, breathing 
patterns and failure rates. 
The presented results can be used when evaluating resistance and dead-space for new 
measurement devices. There are several other aspects of flow measuring techniques that have 
to be evaluated such as drift, need for calibration, effects of gas composition and temperature. 
Safety and general suitability for clinical use also have to be assessed.  
Another limitation to the study is that optimisation for the intended flow range was not 
possible. There were also several flow meters that we wanted to test but were unable to get 
access to. 
The initial assessment of signal quality and flow resistance showed that two devices 
(SFM3200 prototype and Vitalograph Fleisch) had low resistance in combination with an 
acceptable signal quality. If used in the flow-through position they might allow measurement 
of flow without adding resistance or dead-space. 
 
6.3 A NEW RESUSCITATION SYSTEM 
The new resuscitation device was pressure stable when tested in the mechanical lung model 
and showed no increase in imposed WOB at higher levels of CPAP. 
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The clinical feasibility trial showed no problems with safety. The randomisation was not 
stratified on gestational age and infants in the new device with prongs group were smaller 
than infants in the other two groups. A larger proportion of these more immature infants were 
treated with surfactant within 72 hours. The trial was not designed to estimate treatment 
effects and there were no differences in outcome. The verbal feedback from the users was 
that stabilisation with the prongs interface was easier than with facemask. 
The new resuscitation system has unique features that allow exploration of new and revisit 
old research questions:  
1) It can be used to investigate the importance of high and low pressure stability in 
infants during initial stabilisation, after extubation and during procedures such as 
surfactant replacement (by catheters or endotracheal tubes). 
2) It can be used to investigate effects of increased CPAP without the marked increase in 
imposed WOB seen with T-piece systems. 
3) It allows comparison of short bi-nasal prongs and facemask during resuscitation. 
Clinical trials and investigations in these three areas would give valuable contributions even 
if the results were not in favour of the new system. 
 
7 CONCLUSIONS 
We have shown large differences in performance of the different CPAP systems. The clinical 
importance of this is not known. If pressure stability is important, it has to be considered 
when interpreting results or designing trials. The CPAP system (or systems) used in the 
control or treatment groups could attenuate or augment differences in treatment effects. If 
pressure stability is important, it is incorrect to draw generalised conclusions regarding CPAP 
from a trial that has used a particular system or a mix of systems.  
Some systems show a marked increase in imposed WOB with higher levels of CPAP (for 
example Neopuff). Investigating the effects of increasing CPAP with these systems will at the 
same time investigate the effects of increased imposed WOB. 
Flow measurement devices designed for neonatal use have high resistance and imposed work 
of breathing. Measuring flow without adding dead-space or imposed WOB by using the flow-
through technique seems possible. 
A new system for neonatal resuscitation has been designed. The new system has low imposed 
WOB compared to T-piece systems and can be used with either prongs or face mask. A 
feasibility trial revealed no problems with safety or usage. 
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8 TOPICS FOR FUTURE RESEARCH 
8.1 SUMMARY 
The underlying hypothesis driving our research is that non-invasive management is superior 
to intubation and mechanical ventilation for the majority of patients. This commits us to 
research aimed at developing and evaluating non-invasive strategies to avoid intubation and 
mechanical ventilation of preterm infants. 
We have identified four topics that we will focus on over the next few years: 
• What is the clinical effect of differences in performance of NCPAP systems? 
• Can stabilisation using a device with prongs and low imposed WOB during 
resuscitation reduce intubation rates compared to standard T-piece resusciation? 
• Can an updated flow-through system be used as a research or clinical tool? 
• What is the relation between static and dynamic investigations of pressure stability for 
NCPAP systems? 
We have worked with two topics that were part of the original research plan before revision: 
• Can surfactant in nebulised form be administered to infants at high risk of failing on 
NCPAP? 
• Can the function and flows of the Infant Flow NCPAP geometry be explained using 
computational fluid dynamics? 
In addition, two topics for future research that we would like to engage in are: 
• What is the optimal CPAP during resuscitation? 
• What is the in-vitro performance of NIPPV and other types of non-invasive support? 
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9 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Barn som föds för tidigt har omogna lungor och behöver hjälp med att andas. Det vanligaste 
hjälpmedlet för barn som kan andas själva heter nasal CPAP. CPAP är en engelsk förkortning 
för continuous positive airway pressure (kontinuerligt positivt luftvägstryck) och behandling 
med CPAP innebär att barnet har ett mottryck när det andas. Mottrycket har i vetenskapliga 
studier visat sig förbättra lungfunktionen och minska behovet av respiratorvård. 
Målsättningen med denna avhandling är att beskriva kvaliteten hos olika CPAP-system, att 
utvärdera tekniker för att mäta andning och att ta fram ett nytt system för andningshjälp vid 
hjärt-lungräddning av nyfödda. 
Vi har med hjälp av simuleringar i en mekanisk modell kunnat visa att de CPAP-system som 
används idag har olika förmåga att bibehålla ett jämnt luftvägstryck. System som inte klarar 
detta kräver mer arbete av barnet för själva andningen. Förmodligen har detta betydelse vid 
behandlingen, även om det inte är vetenskapligt bevisat. 
Vid forskning och klinisk behandling med CPAP finns ett intresse av att mäta hur barn andas. 
Ett sätt är att mäta luftflöden men det har varit tekniskt svårt att lösa. Vi har i simulerad 
andning undersökt andningsmotstånd och bedömt kvaliteten på flödessignaler för två olika 
mätmetoder. Vi tror att denna teknik kan möjliggöra flödesmätningar utan att belasta barnet 
med extra andningsarbete och återandning av koldioxid.  
När barnet föds måste det själv börja andas och de tidigare vattenfyllda lungorna fyllas med 
luft. CPAP behandling av förtidigt födda barn direkt efter födseln rekommenderas i flera 
behandlingsriktlinjer. Det idag vanligaste hjälpmedlet vid stabilisering av nyföddas andning 
har två egenskaper som skulle kunna vara till nackdel för barnet: Det kräver mycket extra 
andningsarbete och det används bara med en mask som täcker både mun och näsa (till 
skillnad från vanlig näs-CPAP som har en näsmask). Vi har tagit fram ett nytt system för 
hjärt-lungräddning som är lättare för barnet att andas igenom. Det går att använda med både 
ansiktsmask och näsmask. Det nya andningssystemet har testats i en liten studie och vi såg 
inga problem med dess användande. Studien var för liten för att kunna dra slutsatser huruvida 
det nya systemet är bättre eller sämre än det gamla systemet. 
Under de närmaste åren kommer vi att arbeta vidare med flera projekt rörande andningshjälp 
till förtidigt födda barn. Vår målsättning är att undersöka om skillnaderna vi sett mellan olika 
andningssystem i simulerad andning är viktiga för nyfödda barn i verkligheten. För att kunna 
undersöka detta vore en förbättrad teknik för flödesmätning värdefull. Det nya systemet för 
hjärt-lungräddning kommer att testas och jämföras med dagens system i en större studie med 
slumpvis patienturval. Vår förhoppning är att det kan minska antalet förtidigt födda barn som 
behöver vårdas i respirator. 
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